Moderna

Merck and Moderna initiate Phase III INTerpath-009 trial for V940 (mRNA-4157) combined with Keytruda as adjuvant treatment for resectable NSCLC patients not achieving pCR after neoadjuvant Keytruda plus chemotherapy. The trial, enrolling 680 patients globally, aims to assess disease-free survival and other secondary endpoints.

Merck and Moderna initiate INTerpath-009, a Phase 3 trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA for adjuvant treatment of resectable Stage II, IIIA, IIIB (N2) NSCLC patients who did not achieve a pCR after neoadjuvant KEYTRUDA plus platinum-based chemotherapy.

Phase 3 INTerpath-009 trial tests mRNA-4157 neoantigen therapy plus Keytruda for resectable stage 2, 3A, or 3B non-small cell lung cancer not responding to neoadjuvant Keytruda and platinum-based chemotherapy. The trial aims to include 680 patients, with primary outcomes focusing on disease-free survival and distant metastasis-free survival. The estimated primary completion date is May 16, 2033.

Merck and Moderna initiate INTerpath-009, a Phase 3 trial evaluating V940, an individualized neoantigen therapy, combined with Keytruda, as adjuvant treatment for resectable Stage II, IIIA, or IIIB non-small cell lung cancer patients not achieving pathological complete response after neoadjuvant Keytruda plus platinum-based chemotherapy. Recruitment has begun in Canada.

Merck and Moderna initiate Phase 3 trial evaluating mRNA-4157 (V940) in combination with Keytruda after neoadjuvant Keytruda and chemotherapy in patients with resectable Stage II, IIIA, or IIIB (N2) NSCLC who did not achieve a pathological complete response.

Merck & Co Inc and Moderna, Inc. initiated INTerpath-009, a Phase 3 trial of V940 (mRNA-4157) combined with Keytruda for adjuvant treatment in resectable Stage II, IIIA or IIIB (N2) NSCLC patients not achieving pCR after neoadjuvant Keytruda plus platinum-based chemotherapy. Global recruitment has begun, with initial enrollments in Canada. This follows other Phase 3 trials evaluating mRNA-4157 with Keytruda in melanoma and NSCLC, and Phase 2/3 trials in cutaneous squamous cell carcinoma, renal cell carcinoma, and urothelial carcinoma. Results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study showed a 49% reduction in recurrence or death risk with mRNA-4157 plus Keytruda compared to Keytruda alone.

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.

MSD and Moderna initiate phase 3 trial INTerpath-009 for personalized cancer vaccine V940 combined with Keytruda in early-stage non-small cell lung cancer patients, aiming to reduce relapse risk and improve disease-free survival.